Literature DB >> 11349722

Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation.

M S Cauble1, R Gilroy, M F Sorrell, M E Mailliard, D L Sudan, J C Anderson, J L Wisecarver, S Balakrishnan, J L Larsen.   

Abstract

BACKGROUND: Lipoatrophic diabetes is an insulin resistance syndrome characterized by the complete or partial lack of adipose tissue and disturbances in lipid and glucose metabolism. Nonalcoholic steatohepatitis (NASH) is a well-described change in liver pathology consisting of steatosis, hepatitis, and fibrosis that can be associated with lipoatrophic diabetes.
RESULTS: This article describes the first reported case of lipoatrophic diabetes with NASH leading to liver failure and liver transplantation. Before transplantation, the patient required 600-700 U of insulin/day. After transplantation, a dramatic decline in her insulin requirements was observed, despite corticosteroids. Eighteen months after transplantation, her glycemic control worsened, and she developed recurrent NASH on serial liver biopsies.
CONCLUSIONS: NASH associated with lipoatrophic diabetes can recur after liver transplantation, and in this case, was accompanied by increased insulin requirements. These results suggest that the development of NASH itself may contribute to the insulin resistance observed in lipoatrophic diabetes.

Entities:  

Mesh:

Year:  2001        PMID: 11349722     DOI: 10.1097/00007890-200104150-00012

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Focal fat masquerading as malignancy in the liver graft of a post-transplant patient.

Authors:  Caitlyn M Patrick; Paul H Hayashi; Tomasz Kozlowski; Kevin G Greene; Richard C Semelka; A Sidney Barritt
Journal:  Dig Dis Sci       Date:  2011-05-11       Impact factor: 3.199

2.  Effects of Metreleptin in Pediatric Patients With Lipodystrophy.

Authors:  Rebecca J Brown; Cristina Adelia Meehan; Elaine Cochran; Kristina I Rother; David E Kleiner; Mary Walter; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2017-05-01       Impact factor: 5.958

3.  Nonalcoholic fatty liver disease following liver transplantation.

Authors:  Sanjaya Kumar Satapathy; Satheesh Nair; Jason M Vanatta
Journal:  Hepatol Int       Date:  2013-04-26       Impact factor: 6.047

4.  Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.

Authors:  Zahid Ahmad; Lalitha Subramanyam; Lidia Szczepaniak; Vinaya Simha; Beverley Adams-Huet; Abhimanyu Garg
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

Review 5.  Pathogenesis and management issues for non-alcoholic fatty liver disease.

Authors:  Marko Duvnjak; Ivan Lerotić; Neven Barsić; Vedran Tomasić; Lucija Virović Jukić; Vedran Velagić
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

6.  The impact of post-transplant diabetes mellitus on liver transplant outcomes.

Authors:  Sarah R Lieber; Ruth-Ann Lee; Yue Jiang; Claire Reuter; Randall Watkins; Kristen Szempruch; David A Gerber; Chirag S Desai; G Stephen DeCherney; A Sidney Barritt
Journal:  Clin Transplant       Date:  2019-04-23       Impact factor: 3.456

7.  Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD.

Authors:  Samir Softic; Jeremie Boucher; Marie H Solheim; Shiho Fujisaka; Max-Felix Haering; Erica P Homan; Jonathon Winnay; Antonio R Perez-Atayde; C Ronald Kahn
Journal:  Diabetes       Date:  2016-05-10       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.